Mallinckrodt PLC has agreed to acquire Sucampo Pharmaceuticals Inc. for $1.2bn, including the assumption of the latter's debt. The deal most notably brings one significant marketed asset, and two late-stage candidates for rare diseases which are projected to generate up to $450m in peak sales between them, if approved.
The deal helps US-listed, UK-headquartered Mallinckrodt reduce its revenue reliance on controversial specialty medicine H.P.Acthar gel (repository corticotropin injection), which...








